Статья
Артериальная гипертензия и болезнь Альцгеймера. Пролог к нейродегенерации
Нарушения когнитивных функций – глобальная медицинская и социальная проблема всего современного общества. Болезнь Альцгеймера является самым распространенным заболеванием, приводящим к развитию когнитивных нарушений и деменции. Одним из самых значимых факторов риска развития как сосудистой деменции, так и болезни Альцгеймера является артериальная гипертензия. Недавние исследования продемонстрировали роль глимфатической системы в элиминации из головного мозга β-амилоида через периваскулярные пространства Вирхова-Робена. Интерес состоит в том, что адекватное функционирование глимфатической системы в основном зависит от уровня артериального давления в течение суток и качества сна. В данной статье мы рассматриваем основные механизмы влияния артериальной гипертензии на работу глимфатической системы, повреждения вещества головного мозга и развития когнитивных нарушений.
1. Kivipelto M., Helkala E.L., Laakso M.P. et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.
2. Luchsinger J.A., Gustafson D.R. Adiposity, type 2 dia- betes, and Alzheimer’s disease. J Alzheimer’s Dis 2009; 16: 693–704.
3. Ahtiluoto S., Polvikoski T., Peltonen M. et al. Diabetes, Alzheimer disease, and vascular dementia: a population- based neuropathologic study. Neurology 2010; 75: 1195– 1202.
4. Faraco G., Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810– 817.
5. Kaffashian S., Dugravot A., Nabi H. et al. (2011) Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur. Heart J., 32(18): 2326–2332.
6. Diener H.C. (2011) Prevention of dementia should start 20 years before symptoms become apparent. Eur. Heart J., 32(18): 2228–2230.
7. Zlokovic B.V. Neurovascular pathways to neurodegener- ation in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011; 12: 723–738.
8. Qiu L., Ng G., Tan E.K., Liao P., Kandiah N., Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep 2016; 6: 23964.
9. Bennett S.A., Pappas B.A., Stevens W.D., Davidson C.M., Fortin T., Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 2000; 21: 207–214.
10. Weller R.O., Boche D., Nicoll J.A. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neu- ropathol 2009; 118: 87–102
11. Hughes T.M., Craft S., Lopez O.L. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer’s disease. Neurodegener Dis Manag 2015; 5: 121–135.
12. Elkins J. S., Yaffe K., Cauley J. A., Fink H. A. et al. Pre-existing hypertension and the impact of stroke on cognitive function // Ann. Neurol. 2005. Vol. 58. N 1. P. 68–74.
13. Варакин Ю.Я. Профилактика нарушений мозгового кровообращения. Очерки ангионеврологии. Ред. З.А. Суслина. М., 2005.
14. de Leeuw F.E., van Gijn J. Vascular dementia. Pract Neurol, 2003, 3: 86–91.
15. Gorelick P.B. Blood pressure and the prevention of cognitive impairment. JAMA Neurol. 2014;71:1211–3.
16. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499.
17. Bellew K.M., Pigeon J.G., Stang P.E., Fleischman W., Gardner R.M., Baker W.W. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004; 18: 208–213.
18. Starr J. M., Whalley L. J., Inch S., Shering P. A. Blood pressure and cognitive function in healthy old people // J. Am. Geriatr. Soc. 1993. Vol. 41. N 7. P. 153–156.
19. Moonga I., Niccolini F., Wilson H., Pagano G., Politis M. (2017). Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer’s disease. European Journal of Neurology, 24(9), 1173–1182. doi:10.1111/ene.13374
20. Верещагин Н.В., Моргунов В.А., Гулевская Т.С. Патология головного мозга при атеросклерозе и артериальной гипертонии. М., 1997;288 с.
21. Laman J.D., Weller R.O. (2013) Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J. Neuroimmune Pharmacol 8:840–856.
22. Gurol M.E., Viswanathan A., Gidicsin C. et al (2013) Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 73:529–536.
23. Gurol M.E., Irizarry M.C., Smith E.E. et al (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66:23–29.
24. Iliff J.J., Nedergaard M. Is there a cerebral lymphatic system? Stroke. 2013 Jun;44(6):93-95.
25. Xie L., Kang H., Xu Q., et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi:10.1126/science.1241224.
26. Roher A.E., Kuo Y.M., Esh C., Knebel C., Weiss N., Kalback W., Luehrs D.C., Childress J.L., Beach T.G., Weller R.O., Kokjohn T.A. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003;9:112–122.
27. Chabriat H., Joutel A., Dichgans M., Tournier-Lasserve E., Bousser M.G. CADASIL. Lancet Neurol. 2009; 8: 643–653.
28. Zhu Y.C., Tzourio C., Soumare A. et al. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI Markers of small vessel disease: a population-based study. Stroke. 2010;41:2483–2490.
29. Chen H.F., Chang-Quan H., You C., Wang Z.-R., Hui W., Liu Q.X., Si-Qing, H. (2012). The circadian rhythm of arterial blood pressure in Alzheimer disease (AD) patients without hypertension. Blood Pressure, 22(2), 101–105.
30. Salles G. F., Reboldi G., Fagard R. H., Cardoso C. R., Pierdomenico S. D., Verdecchia P., Roush G. C. (2016). Prognostic effect of the nocturnal blood pres- sure fall in hypertensive patients: The Ambulatory Blood Pressure Collaboration in Patients with Hypertension (ABC-H) meta-analysis. Hypertension, 67, 693-700.
31. Verdecchia P. (2000). Prognostic value of ambulatory blood pressure : Current evidence and clinical implications. Hypertension, 35, 844-851. doi:10.1161/01.HYP.35.3.844
32. Fagard R. H., Celis H., Thijs L., Staessen J. A., Clement D. L., De Buyzere M. L., De Bacquer D. A. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension, 51, 55-61. doi:10.1161/ HYPERTENSIONAHA.107.100727
33. O’Rourke M. F., Safar M. E. (2005). Relationship between aortic stiffening and microvascular disease in brain and kidney: Cause and logic of therapy. Hypertension, 46, 200-204.
34. Nagai M., Hoshide S., Ishikawa J., Shimada K., Kario K. (2008). Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. Journal of Hypertension, 26, 1636-1641.
35. Bellelli G., Frisoni G. B., Lucchi E., Guerini F., Geroldi C., Magnifico F., Trabucchi M. (2004). Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with long-standing hypertension. Blood Pressure Monitoring, 9, 71-76.
36. van Boxtel M. P., Henskens L. H., Kroon A. A., Hofman P. A., Gronenschild E. H., Jolles J., de Leeuw P. W. (2006). Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. Journal of Human Hypertension, 20(1), 5-13.
37. Guo H., Tabara Y., Igase M., Yamamoto M., Ochi N., Kido T., . Kohara K. (2010). Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: The J-SHIPP study. Hypertension Research, 33(1), 32-36.
38. Mestre H., Tithof J., Du T., Song W., Peng W., Sweeney A. M., Kelley D. H. (2018). Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nature Communications, 9(1). doi:10.1038/s41467-018-07318-3
39. Mancia G., Fagard R., Narkiewicz K. et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925–38.
40. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of rterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013 Jul;31(7):1281-357.
41. Roth T. Insomnia: definition, prevalence,etiology, and consequences // J Clin Sleep Med., 2007; 3(Suppl 5): S7–10.
42. Полуэктов М.Г., Левин Я.И. Инсомния /Сомнология и медицина сна. Избранные лекции / под ред. Я. И. Левина и М. Г. Полуэктова. – М.: Медфорум-альфа, 2013. – С. 192–220.
43. Ковальзон В.М. Основы сомнологии. Физиология и нейрохимия цикла бодрствование – сон. – М.: БИНОМ. Лаборатория знаний, 2012. – 240 с.
44. Somers V. K., Dyken M. E., Mark A. L., Abboud F. M. (1993). Sympathetic-Nerve Activity during Sleep in Normal Subjects. New England Journal of Medicine, 328(5), 303–307. doi:10.1056/nejm199302043280502
45. Hanak V., Somers V. K. (2011). Cardiovascular and cerebrovascular physiology in sleep. Sleep Disorders, 315–325. doi:10.1016/b978-0-444-52006-7.00019-8
46. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31:1925–1938.
47. Kehoe P. G., Miners S. Love, S. (2009). Angiotensins in Alzheimer’s disease – friend or foe? Trends in Neurosciences, 32(12), 619–628. doi:10.1016/j.tins.2009.07.006